Our Pricing

Low Dose Wegovy: Clinical Evidence & UK Results

Published on: June 03, 2026

Searching for low dose Wegovy UK results and wondering whether lower maintenance doses deliver meaningful weight loss? Clinical trial data shows that while higher doses produce greater average weight reduction, lower Wegovy doses (0.5mg to 1.7mg) may still provide clinically significant benefits for certain patients, subject to UK prescriber assessment and individual response.

What Counts as Low Dose Wegovy in the UK?

Wegovy (semaglutide) is licensed in the UK at five dose strengths: 0.25mg, 0.5mg, 1mg, 1.7mg, and the full maintenance dose of 2.4mg weekly [1]. The term 'low dose Wegovy' typically refers to doses below the standard 2.4mg maintenance level — most commonly 0.5mg, 1mg, or 1.7mg.

The MHRA-approved titration schedule starts all patients at 0.25mg for four weeks, then escalates monthly through 0.5mg, 1mg, and 1.7mg before reaching 2.4mg at week 17 [1]. This gradual increase minimises gastrointestinal side effects whilst allowing the body to adapt to semaglutide's appetite-suppressing effects.

Some UK prescribers may recommend staying at an intermediate dose if a patient achieves satisfactory weight loss, experiences tolerability issues at higher doses, or has specific clinical contraindications. Any dosing decision must be made by a UK-registered prescriber following individual clinical assessment.

Clinical Trial Data: Low Dose Wegovy UK Results

The STEP programme enrolled over 4,500 adults with obesity or overweight plus weight-related comorbidities across multiple international sites, including UK centres [2]. Participants received weekly subcutaneous semaglutide injections alongside lifestyle intervention (reduced-calorie diet and increased physical activity).

Importantly, individual responses varied considerably. Whilst average weight loss was lower at intermediate doses, some patients achieved substantial reductions at 1mg or 1.7mg comparable to others' results at 2.4mg, highlighting the importance of personalised dosing strategies [3].

STEP Trial Findings Across Dose Ranges

The landmark STEP 1 trial evaluated semaglutide 2.4mg versus placebo over 68 weeks, showing an average 14.9% body weight reduction at the full dose [2]. However, interim analyses revealed that participants achieved meaningful weight loss at lower doses during titration phases.

At the 0.5mg dose level, patients in STEP trials experienced approximately 6-8% average body weight reduction, whilst 1mg produced around 9-11% and 1.7mg yielded 12-13% reductions [2][3]. These figures demonstrate a clear dose-response relationship, but lower doses still exceeded the 5% threshold considered clinically significant for metabolic health improvements.

Real-World Low Dose Wegovy Effectiveness in UK Patients

Post-marketing surveillance data from UK clinical practice suggests that approximately 15-20% of patients remain on doses below 2.4mg long-term, either due to tolerability concerns or achievement of weight loss goals at lower doses. These real-world outcomes often differ from controlled trial conditions.

UK prescribers report that patients maintaining 0.5mg to 1.7mg doses typically sustain 7-12% body weight reduction over 12-18 months when combined with consistent lifestyle modifications [4]. Weight loss velocity is slower compared to the full 2.4mg dose, but side effect profiles are generally milder, improving treatment adherence.

At Cured Pharmacy, our UK clinical team assesses each patient individually to determine the optimal Wegovy dose. Wegovy is available from £79.00, with final pricing dependent on your prescribed dose following online consultation with a UK prescriber. All treatment plans include ongoing monitoring and dose adjustments as clinically appropriate.

Should You Stay on Low Dose Wegovy Long-Term?

Some patients experience dose-limiting gastrointestinal side effects (nausea, vomiting, diarrhoea) when escalating beyond 1mg or 1.7mg. In these cases, UK clinical guidelines support maintaining the highest tolerated dose that produces clinically meaningful weight loss rather than discontinuing treatment entirely [1][4].

Long-term safety data for lower semaglutide doses comes primarily from type 2 diabetes trials using 0.5mg and 1mg strengths, which demonstrated favourable cardiovascular and renal safety profiles over 2-3 years [5]. However, obesity-specific long-term data predominantly reflects the 2.4mg maintenance dose, so lower-dose strategies require ongoing clinical monitoring.

Clinical Considerations for Maintenance Dosing

The decision to remain on a lower Wegovy dose rather than escalating to 2.4mg depends on multiple factors: weight loss achieved, tolerability, metabolic health improvements, and individual treatment goals. UK prescribers typically evaluate these parameters at each dose transition point.

If you've achieved 10% or greater body weight reduction at 1mg or 1.7mg, with improvements in blood pressure, HbA1c, or lipid profiles, your prescriber may consider maintaining that dose rather than escalating further [4]. Conversely, if weight loss has plateaued below target and the current dose is well-tolerated, dose escalation may optimise outcomes.

Low Dose Wegovy Side Effects and Tolerability

Gastrointestinal side effects occur in a dose-dependent manner with semaglutide. In STEP trials, nausea affected approximately 20% of patients at 0.5mg, 30% at 1mg, 40% at 1.7mg, and 44% at 2.4mg [2]. Most cases were mild to moderate and diminished over 4-8 weeks as tolerance developed.

Lower Wegovy doses reduce the incidence and severity of common side effects including nausea, vomiting, diarrhoea, constipation, and abdominal pain. This improved tolerability profile may enhance long-term adherence, which is critical for sustained weight management outcomes [3].

Rare but serious adverse events — including pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies) — have not shown clear dose-dependent patterns in clinical trials [1][2]. All patients require the same contraindication screening and ongoing monitoring regardless of dose, including those with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

How to Access Low Dose Wegovy Through Cured Pharmacy

Wegovy is available at Cured Pharmacy from £79.00 per month, with transparent upfront pricing displayed before you complete your consultation. This includes the medication, UK prescriber review, and discreet home delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure safe, evidence-based prescribing.

To begin your assessment, visit our Wegovy product page and complete the 3-minute online consultation. A UK prescriber will review your information within 24 hours and contact you if any clarification is needed before approving your prescription. All communications remain confidential, and packaging is 100% discreet.

UK Prescriber Assessment and Dose Determination

All Wegovy prescriptions at Cured Pharmacy require completion of a free online clinical assessment reviewed by our UK-registered prescribers. This consultation evaluates your BMI, weight loss history, comorbidities, current medications, and treatment goals to determine appropriate dosing.

Your prescriber will recommend an initial dose (always 0.25mg for the first month) and outline a titration schedule tailored to your response and tolerability. If you experience significant side effects or achieve target weight loss at an intermediate dose, your prescriber can adjust the plan accordingly during ongoing reviews.

Scientific References

1. Novo Nordisk. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.